Jun 06, 2018 7:35am EDT Matinas BioPharma to Present Preclinical Data at ASM Microbe 2018 Further Demonstrating the Broad Utility of its LNC Platform
May 10, 2018 7:05am EDT Matinas BioPharma Reports First Quarter 2018 Financial Results and Provides Corporate Update
May 01, 2018 8:05am EDT Matinas BioPharma Selected to Present at the BioNJ Eighth Annual BioPartnering Conference
Apr 19, 2018 8:05am EDT Matinas BioPharma to Present Positive Preclinical Data of MAT2203 at the 28th European Congress of Clinical Microbiology and Infectious Disease
Mar 16, 2018 5:00pm EDT Matinas BioPharma Appoints Jerome D. Jabbour as Chief Executive Officer and Provides Corporate Update
Mar 15, 2018 8:00am EDT Matinas BioPharma to Present at the Oppenheimer 28th Annual Healthcare Conference
Mar 12, 2018 8:05am EDT Matinas BioPharma to Host 2017 Financial Results and Corporate Update Conference Call and Webcast
Jan 08, 2018 7:01am EST Matinas BioPharma Achieves Statistical Endpoint for Success in Phase 2a Clinical Study of Orally-Administered MAT2203 for the Treatment of Chronic Refractory Mucocutaneous Candidiasis
